RxDoctor Payments Data

Halee Essick, NP

Nurse Practitioner · du Quoin, ILNPI 1770295719

Payments from drug & device makers

$4,265in general payments, 2019–2025

Across 177 payments — averaging $24.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Regeneron Healthcare Solutions, Inc.$533
  • Sanofi$491
  • GSK$401
  • Mallinckrodt Hospital Products Inc.$226
  • Mylan Specialty L.p.$202
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,98593%
  • Education$2807%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,265 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$58,312
Medicare patients
293
Services billed
822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter478$358,009
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr143$74,863
Breztri AerosphereBudesonide/Glycopyr/Formoterol89$61,091
Dupixent PenDupilumab15$52,615
Breo ElliptaFluticasone/Vilanterol67$29,798
Spiriva RespimatTiotropium Bromide26$16,186
Incruse ElliptaUmeclidinium Bromide34$15,665
DuleraMometasone/Formoterol42$15,516
Stiolto RespimatTiotropium Br/Olodaterol Hcl29$15,326
Combivent RespimatIpratropium/Albuterol Sulfate31$14,905
Albuterol Sulfate HfaAlbuterol Sulfate379$14,108
Bevespi AerosphereGlycopyrrolate/Formoterol Fum26$11,449
Ventolin HfaAlbuterol Sulfate107$7,491
SymbicortBudesonide/Formoterol Fumarate15$5,780
Varenicline Tartrate22$4,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$401$478,335722 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$1,192$78,320130 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$50$46,41786 claims
MerckDulera$41$15,51642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in du Quoin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →